PanGenomic Health Inc. (CSE: NARA) (AQSE: NARA), a pioneering precision health company, has announced its plan to delist its Class A Common Shares from the Aquis Stock Exchange Growth Market (AQSE).
The Vancouver-based firm cited sparse trading volume on the AQSE’s Access Market segment as the primary reason behind its decision.
According to the AQSE Access Rulebook, PanGenomic Health is obligated to provide a 20-business day notice ahead of its withdrawal. Consequently, the trading of its shares on the AQSE will come to a halt at 4:30 pm UK time on March 15, 2024.
However, the company’s shares will continue to be available on the Canadian Securities Exchange under the ticker “NARA”, as well as on the Frankfurt, Berlin, Hamburg, Stuttgart, and Munich Stock Exchanges with the symbol “LL30”.
This step reflects the directors’ response to the limited engagement of the company’s shares on the AQSE since its initial listing. The announcement carries inside information as per Article 7 of the Market Abuse Regulation (EU) 596/2014, as incorporated into UK law, and complies with the disclosure obligations stipulated by Article 17 of the same regulation.
PanGenomic Health is known for its innovative approach to precision health, focusing on a digital platform that offers personalized, scientifically backed insights into natural treatments, particularly for mental health.
As a benefit corporation registered in British Columbia, the company is committed to leveraging technology to identify plant-based health solutions tailored to individual health profiles, aiming to enhance the overall well-being of society and its people. – BusinessNewsAsia.com